FibroBiologics (FBLG) Free Cash Flow (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Free Cash Flow of -$3.3 million for Q2 2026, up 21.59% year-over-year from -$2.7 million in Q2 2025, and up 24.59% on a QoQ basis from -$4.4 million in Q1 2026.
FibroBiologics (FBLG) Free Cash Flow (2023 - 2026) Analysis & Trends
FibroBiologics has reported Free Cash Flow for 4 years, with the latest figure at -$3.3 million in Q2 2026.
- Free Cash Flow for Q2 2026 came in at -$3.3 million, up 21.59% year-over-year; the trailing twelve-month figure through Jun 2026 was -$14.8 million (up 3.32% YoY), and the FY2025 annual result was -$16.7 million, down 37.82% from the prior year.
- Free Cash Flow climbed to -$3.3 million in Q2 2026, from -$4.4 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$1.6 million in Q3 2023 and troughed at -$5.3 million in Q1 2025.
- A 4-year average of -$3.1 million and a median of -$3.2 million in 2024 frame the typical range for Free Cash Flow.
- The widest annual swing landed in 2025, when Free Cash Flow plunged 108.49%; it then advanced 21.59% in 2026.
- A 4-year view of Free Cash Flow shows it stood at -$1.6 million in 2023, then tumbled by 97.88% to -$3.2 million in 2024, then rose by 0.28% to -$3.2 million in 2025, then dropped by 4.05% to -$3.3 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were -$3.3 million in Q2 2026, -$4.4 million in Q1 2026, and -$3.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - | -3.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.29 Mn |
| Jun 30, 2026 | -3.29 Mn |
| Mar 31, 2026 | -4.36 Mn |
| Mar 31, 2026 | -4.36 Mn |
| Dec 31, 2025 | -3.16 Mn |
| Dec 31, 2025 | -3.16 Mn |
| Sep 30, 2025 | -3.98 Mn |
| Sep 30, 2025 | -3.98 Mn |
| Jun 30, 2025 | -4.20 Mn |
| Jun 30, 2025 | -4.20 Mn |
| Mar 31, 2025 | -5.32 Mn |
| Mar 31, 2025 | -5.32 Mn |
| Dec 31, 2024 | -3.17 Mn |
| Dec 31, 2024 | -3.17 Mn |
| Sep 30, 2024 | -2.62 Mn |
| Sep 30, 2024 | -2.62 Mn |
| Jun 30, 2024 | -2.01 Mn |
| Jun 30, 2024 | -2.01 Mn |
| Mar 31, 2024 | -4.28 Mn |
| Mar 31, 2024 | -4.28 Mn |